Maria Cherska: Exploring the Role of Fucoidan in Metabolic Liver Disease
Maria Cherska, The head of cardiology department at The State Institution «V.P. Komisarenko Institute of Endocrinology and Metabolism», shared a post on LinkedIn about a recent article by Xueru Chu et al., published in Lipids in Health and Disease։
“NAFLD/MASLD remains one of the most important cardiometabolic challenges worldwide – and this publication nicely highlights the role of oxidative stress and inflammation in disease progression.
A very interesting study recently published in Lipids in Health and Disease, demonstrated that fucoidan reduced lipid accumulation, oxidative stress, and NF-κB-mediated inflammation in a 3D NAFLD spheroid model through regulation of the PI3K/AKT/Nrf2 signaling pathway.
Particularly interesting:
- use of an advanced 3D spheroid NAFLD model;
- focus on oxidative stress and inflammatory pathways;
- potential future role of nutraceutical and functional food approaches in metabolic medicine.
Great to see this kind of translational and mechanistic research published in Lipids in Health and Disease – an important journal in the field of lipid metabolism, cardiometabolic diseases, and preventive medicine.”
Title: Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model
Authors: Xueru Chu, Xuan Wang, Keqing Feng, Yanzhen Bi, Yongning Xi, Shousheng Liu

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series